Lilly Medical Affairs
K

SERDS: Relevance and Role in Current & Future Treatments for HR+, HER2- MBC

By Lilly Medical Affairs FEATURING Komal Jhaveri
By Lilly Medical Affairs FEATURING Komal Jhaveri
404 views
July 24, 2024

In this video, Dr. Komal Jhaveri shares her expertise on SERDs for the treatment of HR+, HER2- MBC, including the evolving role of novel oral SERDs.

To access additional videos and download free resources, click here.

VV-OTHR-US-DEL-3129 © 2024 Lilly USA, LLC. All Rights Reserved.

Comments are disabled for this content.

Featured Video

06:14
Lilly Medical Affairs

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Feat. J. O’Shaughnessy

Featured Video

05:15
Lilly Medical Affairs

Unmet Needs for Patients With HR+, HER2- Early Breast Cancer at a Hi…

Feat. H. Rugo

Recommended

AUTOPLAY
02:58

A Heterogenous Disease with Varied Clinical Outcomes: HR+/HER2- MBC

Lilly Medical Affairs

J. O’Shaughnessy

438 views
06:14

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Lilly Medical Affairs

J. O’Shaughnessy

467 views
05:59

Progression on First-Line Therapy in HR+, HER2- MBC: Treatments and …

Lilly Medical Affairs

J. O’Shaughnessy

583 views
03:57

Resistance Mechanisms to ET, Including ESR1 Mutations in HR+, HER2- …

Lilly Medical Affairs

K. Jhaveri

450 views
03:15

New

Unmet Needs and Resistance Mechanisms in Patients With HR+, HER2- MB…

Lilly Medical Affairs

W. Mchayleh

23 views
25:08

ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice

2024 ASCO® Annual Meeting Insights Hub

S. Tolaney, H. Rugo

3.9K views
12:14

ASCO® 2024 Breast Cancer Highlights: Top 5 Abstracts - DESTINY-Breas…

2024 ASCO® Annual Meeting Insights Hub

P. Tarantino

2.0K views
11:31

ASCO® 2023 Top 5 Abstracts Summary: "SONIA, NATALEE, PHERGain, TROPI…

Insights from 2023 ASCO® Annual Meeting

P. Tarantino

8.2K views
10:53

Integrating Oral Therapy for Patients With HR+/HER2- Early Stage BC

Kirollos Hanna

2.1K views
07:23

Advanced Stage HR+ BC: Fine-Tuning Sequential Endocrine and Targeted…

Total Health

R. O'Regan

1.3K views
12:35

SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+ mBC?"

Insights from 2023 SABCS

S. Tolaney, H. Rugo

3.0K views
09:55

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future Hold?"

2024 ASCO® Annual Meeting Insights Hub

E. Hamilton

1.3K views
03:40

SABCS 2023 Insights: "CAPItello-291 Trial - Capivasertib & Fulvestra…

Integrity CE

A. Bardia

1.5K views
14:16

Year in Review: Breast Cancer

Dana-Farber Cancer Institute

P. Tarantino

2.4K views
17:12

Strategies for Managing Toxicities of Oral Oncolytics in Breast Canc…

UNC Lineberger Comprehensive Cancer Center

A. Faso, B. Patel, K. Chen

1.4K views
17:39

2023 Menopause Update

Yale School of Medicine

M. Minkin

8.9K views
14:52

ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-…

2024 ESMO Annual Meeting Insights Hub

P. Tarantino

649 views
06:40

New

FDA Approval Clinical Implications: Inavolisib With Palbociclib and …

Memorial Sloan Kettering Cancer Center

K. Jhaveri

433 views
17:50

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

1.8K views
05:43

Neoadjuvant Chemo for HR+ BC: Year in Review

Total Health

C. Ma

958 views